Theo Hirsch

Hepatocellular carcinoma is the most common primary liver cancer and remains a leading cause of cancer related mortality worldwide. Despite major advances in systemic therapy, including atezolizumab plus bevacizumab, only around 30% of patients derive meaningful benefit, and clinicians still lack reliable biomarkers to guide treatment decisions. 🧬A critical unmet need in HCC care is the ability to predict who will respond to immunotherapy and to monitor treatment effectiveness early. Without this, many patients are exposed to ineffective therapy and unnecessary toxicity, while losing valuable time to switch strategies. 🎓A new #EASLfellowship project by Claudia Campani, ​Centre de Recherche des Cordeliers, Paris addresses this challenge by developing a serum based proteomic signature for patients with advanced HCC treated with atezolizumab and bevacizumab. Using high throughput Olink® technology, more than 5,000 circulating proteins were analysed in 88 patients, leading to the identification of 35 proteins strongly associated with both progression free and overall survival. These promising candidates will now be validated in an independent multicentre cohort of 120 patients using multiplex ELISA, a cost effective and clinically feasible approach. 🔍By integrating baseline and longitudinal biomarker analyses, this project aims to deliver a non invasive tool to improve prognostic stratification and early treatment monitoring. Ultimately, it seeks to support a more personalised, biomarker driven approach to #HCC management, maximising therapeutic benefit while sparing patients from ineffective treatments. @DebbieShawcros1 @analleo

Happy to share our latest study @Nature , where we evaluate somatic evolution and the effect of treatment in normal tissue using duplex sequencing 1/n nature.com/articles/s4158…